DE69618999T2 - Farnesyltransferase hemmende 2-chinolonderivate - Google Patents

Farnesyltransferase hemmende 2-chinolonderivate

Info

Publication number
DE69618999T2
DE69618999T2 DE69618999T DE69618999T DE69618999T2 DE 69618999 T2 DE69618999 T2 DE 69618999T2 DE 69618999 T DE69618999 T DE 69618999T DE 69618999 T DE69618999 T DE 69618999T DE 69618999 T2 DE69618999 T2 DE 69618999T2
Authority
DE
Germany
Prior art keywords
chinolon
derivatives
farnesyl transferase
transferase inhibiting
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69618999T
Other languages
English (en)
Other versions
DE69618999D1 (de
Inventor
William End
Gaston Venet
Rene Angibaud
Charles Sanz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of DE69618999D1 publication Critical patent/DE69618999D1/de
Application granted granted Critical
Publication of DE69618999T2 publication Critical patent/DE69618999T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
DE69618999T 1995-10-31 1996-10-25 Farnesyltransferase hemmende 2-chinolonderivate Expired - Lifetime DE69618999T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95202945 1995-10-31
PCT/EP1996/004661 WO1997016443A1 (en) 1995-10-31 1996-10-25 Farnesyl transferase inhibiting 2-quinolone derivatives

Publications (2)

Publication Number Publication Date
DE69618999D1 DE69618999D1 (de) 2002-03-14
DE69618999T2 true DE69618999T2 (de) 2002-09-26

Family

ID=8220785

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69632751T Expired - Lifetime DE69632751T2 (de) 1995-10-31 1996-10-25 Farnesyltransferase hemmende 2-Chinolonderivate
DE69618999T Expired - Lifetime DE69618999T2 (de) 1995-10-31 1996-10-25 Farnesyltransferase hemmende 2-chinolonderivate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69632751T Expired - Lifetime DE69632751T2 (de) 1995-10-31 1996-10-25 Farnesyltransferase hemmende 2-Chinolonderivate

Country Status (29)

Country Link
US (1) US5968952A (de)
EP (2) EP1106610B1 (de)
JP (1) JP4257869B2 (de)
KR (1) KR100417620B1 (de)
CN (1) CN1101391C (de)
AR (1) AR004699A1 (de)
AT (2) ATE212627T1 (de)
AU (1) AU712435B2 (de)
CA (1) CA2231143C (de)
CY (1) CY2287B1 (de)
CZ (1) CZ290954B6 (de)
DE (2) DE69632751T2 (de)
DK (1) DK1019395T3 (de)
EA (1) EA000719B1 (de)
ES (2) ES2171736T3 (de)
HK (2) HK1027576A1 (de)
HU (1) HU224032B1 (de)
IL (1) IL123567A (de)
MY (1) MY116577A (de)
NO (1) NO314037B1 (de)
NZ (1) NZ321576A (de)
PL (1) PL184168B1 (de)
PT (1) PT1019395E (de)
SI (1) SI1019395T1 (de)
SK (1) SK282642B6 (de)
TR (1) TR199800720T2 (de)
TW (1) TW349948B (de)
WO (1) WO1997016443A1 (de)
ZA (1) ZA969087B (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1231215C (zh) * 1997-06-02 2005-12-14 詹森药业有限公司 (咪唑－5－基)甲基－2－喹啉酮衍生物用作平滑肌细胞增殖抑制剂
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
CA2312720A1 (en) * 1997-12-11 1999-06-17 Janssen-Cilag S.A. Retinoic acid mimetic anilides
WO1999065898A1 (en) * 1998-06-16 1999-12-23 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Imidazolyl derivatives
US6420555B1 (en) 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
KR100591603B1 (ko) * 1998-07-06 2006-06-20 얀센 파마슈티카 엔.브이. 생체내 방사선 감작성을 갖는 파네실 단백질 트랜스퍼라제억제제
US6451812B1 (en) 1998-07-06 2002-09-17 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating arthropathies
FR2780892B1 (fr) * 1998-07-08 2001-08-17 Sod Conseils Rech Applic Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
AU4925199A (en) * 1998-08-27 2000-03-21 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
CN1314904A (zh) 1998-08-27 2001-09-26 辉瑞产品公司 用作抗癌剂的炔基取代的喹啉－2－酮衍生物
AU2477400A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6316436B1 (en) 1998-12-08 2001-11-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
IL143859A0 (en) 1998-12-23 2002-04-21 Janssen Pharmaceutica Nv 1,2-annelated quinoline derivatives
SK11002001A3 (sk) * 1999-02-11 2002-05-09 Pfizer Products Inc. Heteroarylom substituované chinolin-2-ónové deriváty použiteľné ako protinádorové prostriedky
US6143766A (en) * 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
EP1420015A1 (de) * 1999-06-11 2004-05-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Imidazol-Derivate
EP1106612B1 (de) * 1999-11-30 2004-02-11 Pfizer Products Inc. Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
AU2001231763A1 (en) 2000-02-24 2001-09-03 Janssen Pharmaceutica N.V. Dosing regimen
CA2397448A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
EP1265611A2 (de) * 2000-02-29 2002-12-18 Janssen Pharmaceutica N.V. Kombinationen von farnesyl-protein-transferase-inhibitoren mit taxanen
CA2397694A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica Inc. Farnesyl protein transferase inhibitor combinations
CA2397253A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
JP2003525238A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗腫瘍性ポドフィロトキシン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
EP1261348A2 (de) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Kombination von farnesyl proteintransferase inhibitoren mit stickstoff-senf oder nitrosoharnstoff alkylierungsmitteln
CA2397475A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
CA2397240A1 (en) * 2000-02-29 2001-09-07 Peter Albert Palmer Farnesyl protein transferase inhibitor combinations with camptothecin compounds
AU2001256166A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
WO2001064226A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
AU2001254672A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with an her2 antibody
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
JO2361B1 (en) * 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
JP4974439B2 (ja) * 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
EP1322636A1 (de) * 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. 6-(substituierte phenyl)methyl)chinolin- und chinazolinderivate und deren verwendung als farneyl transferase inhibitoren
DE60118225T2 (de) * 2000-09-25 2007-05-03 Janssen Pharmaceutica N.V. Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
ES2328225T3 (es) * 2000-11-21 2009-11-11 Janssen Pharmaceutica Nv Derivados benzoheterociclicos inhibidores de la farnesil-transferasa.
AU2002218311A1 (en) * 2000-11-28 2002-06-11 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
CA2432137C (en) 2000-12-19 2010-12-21 Pfizer Products Inc. Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
ATE325116T1 (de) * 2000-12-27 2006-06-15 Janssen Pharmaceutica Nv Farnesyltransferasehemmende 4- heterocyclylchinolin- und chinazolinderivate
EP1347966B1 (de) * 2000-12-27 2006-03-08 Janssen Pharmaceutica N.V. Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
US20040110769A1 (en) * 2001-02-15 2004-06-10 End David William Farnesyl protein transferase inhibitor combinations with antiestrogen agents
ATE287882T1 (de) 2001-03-12 2005-02-15 Janssen Pharmaceutica Nv Verfahren zur herstellung von imidazolverbindungen
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
US7408063B2 (en) 2001-12-19 2008-08-05 Janssen Pharmaceutica, N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
JP4450628B2 (ja) * 2002-03-22 2010-04-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼインヒビターとして使用するためのベンジルイミダゾリル置換２−キノリンおよびキナゾリン誘導体
US7511138B2 (en) 2002-04-15 2009-03-31 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
FR2841243B1 (fr) * 2002-06-19 2004-08-20 Servier Lab Nouveaux derives de 3-(4-oxo-4h-chromen-2yl)-(1h)-quinolein- 4-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030125268A1 (en) * 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
FR2860235A1 (fr) * 2003-09-29 2005-04-01 Yang Ji Chemical Company Ltd Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
NZ554545A (en) * 2004-09-17 2010-10-29 Whitehead Inst Of Biomedical R Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
US20060111398A1 (en) 2004-11-05 2006-05-25 Fourie Anne M Therapeutic use of farnesyltransferase inhibitors and methods of monitoring the efficacy thereof
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US20060281769A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281755A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20070004660A1 (en) * 2005-06-10 2007-01-04 Baumann Christian A Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US7833339B2 (en) 2006-04-18 2010-11-16 Franklin Industrial Minerals Mineral filler composition
EP2545919A1 (de) 2005-12-23 2013-01-16 Link Medicine Corporation Behandlung von Synucleinopathien
SI2021335T1 (sl) * 2006-04-20 2011-09-30 Janssen Pharmaceutica Nv Heterocikliäśne spojine kot zaviralci c-fms kinaze
EP2016074B1 (de) 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitoren von c-fms-kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
DE102007015709B4 (de) 2007-01-25 2009-09-03 Webasto Ag Fahrzeugdach
TW200911262A (en) 2007-06-05 2009-03-16 Schering Corp Novel compounds that are ERK inhibitors
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
US8232402B2 (en) 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
WO2009117484A2 (en) 2008-03-18 2009-09-24 University Of South Florida Small molecule e2f inhibitor
BRPI0920927A2 (pt) 2008-11-13 2019-09-24 Link Medicine Corp derivados de azaquinolinona e usos dos mesmos
EP2483263B1 (de) 2009-09-30 2018-07-18 Merck Sharp & Dohme Corp. Heterocyclische verbindungen als erk-hemmer
US8481553B2 (en) 2010-04-06 2013-07-09 Brigham Young University Antimetastatic compounds
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
JP6034784B2 (ja) 2010-07-28 2016-11-30 ジャンセン ダイアグノスティックス，エルエルシー ファルネシルトランスフェラーゼ阻害剤による治療に対する急性白血病応答を判定するための方法
JP2013536241A (ja) * 2010-08-24 2013-09-19 ブリガム・ヤング・ユニバーシティ 抗転移化合物
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2654748B1 (de) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
US9175001B2 (en) 2011-10-02 2015-11-03 Trustees Of Boston University [1,3] dioxolo [4,5-g] [1,2,4] triazolo [1,5-a] quinoline derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer
IN2015DN00659A (de) 2012-08-07 2015-06-26 Janssen Pharmaceutica Nv
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
WO2015119249A1 (ja) 2014-02-07 2015-08-13 国立大学法人東京医科歯科大学 筋形成促進剤、筋萎縮抑制剤、医薬組成物及びｔａｚ活性化剤
TWI710642B (zh) 2015-08-17 2020-11-21 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶（farnesyltransferase）抑制劑治療癌症病患之方法
EP3133066A1 (de) 2015-08-21 2017-02-22 Merck Patent GmbH Hydrophile verbindungen zur herstellung von optisch aktiven vorrichtungen
US9815790B2 (en) 2015-08-27 2017-11-14 Janssen Pharmaceutica Nv Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists
EP3534885B1 (de) 2016-11-03 2021-01-20 Kura Oncology, Inc. Farnesyltransferase-inhibitoren zur verwendung bei der behandlung von krebs
EP3363786A1 (de) 2017-02-15 2018-08-22 Merck Patent GmbH Verbindungen für optisch aktive vorrichtungen
EP3363793A1 (de) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobe verbindungen zur herstellung von optisch aktiven vorrichtungen
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3900501A (en) * 1970-12-23 1975-08-19 Hoffmann La Roche Benzophenone intermediates for 7-lower alkanoyl benzodiazepines
IL65709A (en) * 1981-05-18 1986-01-31 Chevron Res Electroactive polymers
JPS63275548A (ja) * 1987-05-02 1988-11-14 Res Inst For Prod Dev ｏ−アミノベンゾイル化合物の製造方法
CA2002864C (en) * 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
EP0574992A1 (de) * 1992-06-17 1993-12-22 Glaxo Group Limited 5-(1,2,4-Triazol-1-Ylmethyl)-3H-Isobenzofuran-1-Onderivate, ihre Herstellung und Verwendung als Aromatasinhibitoren
ES2134971T3 (es) * 1994-04-15 1999-10-16 Takeda Chemical Industries Ltd Derivado de acido octahidro-2-naftaleno-carboxilico, su produccion y uso.

Also Published As

Publication number Publication date
MY116577A (en) 2004-02-28
CA2231143C (en) 2005-06-21
AR004699A1 (es) 1999-03-10
DE69632751T2 (de) 2005-08-04
HUP9802424A3 (en) 2003-02-28
KR19990063639A (ko) 1999-07-26
EA000719B1 (ru) 2000-02-28
TR199800720T2 (xx) 1998-09-21
PL184168B1 (pl) 2002-09-30
EP1106610A1 (de) 2001-06-13
ES2171736T3 (es) 2002-09-16
AU7493396A (en) 1997-05-22
WO1997016443A1 (en) 1997-05-09
IL123567A0 (en) 1998-10-30
ATE269322T1 (de) 2004-07-15
EA199800395A1 (ru) 1998-10-29
DE69632751D1 (de) 2004-07-22
TW349948B (en) 1999-01-11
MX9802067A (es) 1998-08-30
CN1200732A (zh) 1998-12-02
CY2287B1 (en) 2003-07-04
ZA969087B (en) 1998-04-29
JPH11514635A (ja) 1999-12-14
PT1019395E (pt) 2002-07-31
DK1019395T3 (da) 2002-05-06
ES2233557T3 (es) 2005-06-16
ATE212627T1 (de) 2002-02-15
CZ127298A3 (cs) 1998-12-16
EP1019395A1 (de) 2000-07-19
CA2231143A1 (en) 1997-05-09
HU224032B1 (hu) 2005-05-30
AU712435B2 (en) 1999-11-04
SK282642B6 (sk) 2002-10-08
NO980928D0 (no) 1998-03-04
NO314037B1 (no) 2003-01-20
CN1101391C (zh) 2003-02-12
NO980928L (no) 1998-04-29
HK1036064A1 (en) 2001-12-21
PL328230A1 (en) 1999-01-18
IL123567A (en) 2002-11-10
KR100417620B1 (ko) 2004-05-27
NZ321576A (en) 1999-05-28
US5968952A (en) 1999-10-19
HUP9802424A2 (hu) 1999-10-28
DE69618999D1 (de) 2002-03-14
EP1019395B1 (de) 2002-01-30
HK1027576A1 (en) 2001-01-19
CZ290954B6 (cs) 2002-11-13
SI1019395T1 (en) 2002-06-30
SK55698A3 (en) 1999-02-11
JP4257869B2 (ja) 2009-04-22
EP1106610B1 (de) 2004-06-16

Similar Documents

Publication Publication Date Title
DE69618999T2 (de) Farnesyltransferase hemmende 2-chinolonderivate
IL123155A0 (en) 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors
DK1162201T3 (da) Farnesylproteintransferaseinhiberende (imidazol-5-yl)methyl-2-quinolinonderivater
EE9700314A (et) Farnesüül-proteiini transferaasi inhibiitorid
ATE185341T1 (de) 4,9-ethano-benzo(f)isoindolderivate als farnesyl transferase inhibitoren
KR970701689A (ko) 이소프레닐 전이효소 억제제
DK0948483T3 (da) Farnesyltransferaseinhibitorer
IL141626A0 (en) Farnesyl transferase inhibitors
DE29505356U1 (de) Fluidverteiler
ZA971254B (en) Farnesyl transferase inhibitors
IL155594A0 (en) Farnesyl transferase inhibitors
SI0948483T1 (en) Farnesyl transferase inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition